NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI announced late on Thursday its intention to complete a non-brokered private placement of more than 5 million units to raise gross proceeds of up to C$9 million (US$9 million).

The Toronto-based firm said it plans to place up to 5,142,857 units for C$1.75 per unit. Each unit will consist of one common share and one common share purchase warrant, which will entitle its holder to purchase one common share for C$2.50 for a period of two years from the date of issuance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.